←
Mark Jit112 posts
Mark Jit avatar

Mark Jit

@markjit

Modeller, epidemiologist, economist at @LSHTM, visiting prof at @HKUniversity, previously at Public Health England. Interested in vaccines, infectious diseases.

◷ Joined March 2009
Richard White avatar
⟳ Mark Jit retweeted
Richard White@richardwhite321·24 Apr 2024

We asked a range of key decision-makers what they need to know to about potential new vaccines The results were..... Alot, and WHO's Full Value of Vaccine Assessments framework helps But FVVAs could be even more useful Our new paper gives 3 ways FVVAs could be even better:

Post attachment
Mark Jit avatar
Mark Jit@markjit·7 Dec 2023

(2/2) "Modeling needs to be supported by infrastructure for systems to collect and share data, model development, and collaboration between groups, as well as two-way engagement between modelers and both policy makers and the public."

Mark Jit avatar
Mark Jit@markjit·7 Dec 2023

(1/2) 15 modellers in 7 countries from projects Epipose and @ESCAPEpandemics reflect on lessons learnt from modelling the COVID-19 pandemic, in the specal COVID-19 issue from @Health_Affairs. healthaffairs.org/doi/full/1…

Naomi Waterlow avatar
⟳ Mark Jit retweeted
Naomi Waterlow@N_R_Waterlow·1 Sep 2023

Thanks to co-authors @mert0248, Edwin van Leeuwen, @VetSree, @markjit and @rozeggo! Also for a fuller understanding of the cost-effectiveness of such vaccines check out our other paper, answering similar questions in a completely different setting! bmcmedicine.biomedcentral.co…

Mark Jit avatar
Mark Jit@markjit·30 Aug 2023

We are still far from reaching WHO's target of bringing HPV vaccines to 90% of girls before age 15. Excited by opportunities that 1-dose vaccine schedules offer to help bring HPV vaccines to more people. This paper led by @kiesha_prem is a key piece of evidence to inform this.

Our recently published global impact and cost-effectiveness employed comparative modelling to evaluate outcomes of 1-dose vs 2-dose HPV vaccination schedules @BMCMedicine doi.org/10.1186/s12916-023-0… ✨@EmilyAnnika @jflaprise @hadley_liza @AllisonPortnoy @markjit @cmmid_lshtm +++✨

Mark Jit avatar
Mark Jit@markjit·4 Jul 2023

Great that WHO's Full Value of Vaccines Assessment framework is now published in @BMCMedicine . This has been used by WHO + collaborators to assess many recent vaccines in development. rdcu.be/df00V

Mark Jit avatar
Mark Jit@markjit·1 Jun 2023

Fantastic that @TheEconomist are highlighting the global disparities around HPV vaccine uptake as well as the opportunity we have to end cervical cancer as public health problem.

In 2020 cervical cancer killed 342,000 women 🌍 95% of cervical #cancer cases are caused by #HPV @TheEconomist uses model by Kaja Abbas & @markjit to estimate successful global HPV #vaccine initiative could reduce cervical cancer deaths by 2.65m by 2030💉📉👇

Mark Jit avatar
Mark Jit@markjit·18 May 2023

I'm delighted and humbled by this news. The award is really a testament to the dedication of my colleagues at LSHTM and around the world. I am so grateful for your support, encouragement and inspiration throughout my journey. Thank you!

Congratulations to LSHTM’s @markjit for being elected a Fellow of @acmedsci 🎉 Mark joins 59 influential scientists from UK institutions awarded the prestigious fellowship this year, for helping advance biomedical & health science.🔬#AMSFellows2023 👉https://t.co/kgF6tYHawu

Post attachment
Hugo C Turner avatar
⟳ Mark Jit retweeted
Hugo C Turner@hugocturner·15 May 2023

1) In our recent review we introduce what are economic costs and why they are used in health economic studies @Downey1L @AnnaVassall @HITAP_Thailand @markjit resource-allocation.biomedce…

Mark Jit avatar
Mark Jit@markjit·16 May 2023

This new collection we put together shows most RSV burden is in very young infants in KE and ZA. So new RSV vaccines and mAbs could be even more cost-effective in some LMICs than recognised. Results of tremendous work by @nicd_sa @KEMRI_Kenya @PATHtweets @LSHTM investigators.

Underlining the collections' findings on RSV burden @PSrikantiah and @findingpneumo discuss the data included in the collection and the scale of RSV burden. @gatesfoundation bmcmedicine.biomedcentral.co…

Rebecca Clark avatar
⟳ Mark Jit retweeted
Rebecca Clark@ra_clark18·15 Mar 2023

The first paper for my PhD thesis is now available at @LancetGH! 🎉 Our modelling shows that introducing new #TB #vaccines are likely to have a substantial health impact in LMICs 🗺️🦠💉 From @lshtm_tbmod @LSHTM_TB @LSHTM_Vaccines @cmmid_lshtm @LSHTM thelancet.com/journals/langl…